Effect of melatonin in treatment of schizophrenia
Phase 3
Recruiting
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT20210528051416N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Patients who have admitted in psychiatry ward of Golestan hospital
Age 18-65 years
Schizophrenic patient according to DSM-5
Satisfaction of patients' guardianship
Schizophrenic patients who have treated with risperidone
Exclusion Criteria
Treatment with any psych medications except for risperidone
Comorbidity of other psychopathologies
Abuse of any substance, drug, or alcohol
Drug reaction to melatonin or placebo
Past history of treatment with clozapine or melatonin
Pregnancy, mental retardation or any other neurologic and neurocognitive disorders, sleep apnea
Proven depression according to Calgary scale
Treatment with ECT in the current episode
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score of positive and negative symptoms according to PANSS scale. Timepoint: At the start of intervention, 3 weeks and 6 weeks later. Method of measurement: positive and negative syndrome scale.
- Secondary Outcome Measures
Name Time Method